Concepedia

Publication | Open Access

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

DOIFull Paper Access

806

Citations

17

References

2021

Year

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean‐François Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood,
New England Journal of Medicine

Abstract

Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).

References

YearCitations

Page 1